PROYECTOS CONVOCATORIA PÚBLICA

Proyecto PI16/00002

HVEM / BTLA / CD160 Y PD-L1/PD1 como dianas inmunoterapéuticas en el tratamiento de tumores hematopoyéticos

Financiador: INSTITUTO DE SALUD CARLOS III (ISCIII)

Duración del 02 de abril de 2019 al 30 de septiembre de 2020 (18 meses) Finalizó

23.740,70 EUR

De ámbito Nacional.

Convocatoria: (INSTITUTO DE SALUD CARLOS III (ISCIII))

Investigadores/as

Foto de Mª LUISA DEL

Responsable

Foto de JOSE IGNACIO

RODRÍGUEZ BARBOSA

Publicaciones relacionadas con el proyecto (5)

Mostrar por tipología

2024

Assesment of Hypoderma infestation in a wild population of Cervus elaphus from mountains Atlantic ecosystems in southwestern Europe (Spain)
Veterinary Research Communications

2023

Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
Frontiers in Immunology

2022

The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
Translational Research
Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
Frontiers in Immunology

2020

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model
Cancer Immunology, Immunotherapy